{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03651791",
      "OrgStudyIdInfo": {
        "OrgStudyId": "USPIO-MSC1"
      },
      "Organization": {
        "OrgFullName": "Rigshospitalet, Denmark",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "In Vivo Tracking of USPIO Labeled MSC in the Heart",
      "OfficialTitle": "In Vivo MRI Tracking of Mesenchymal Stromal Cells Labeled With Ultra-Small Paramagnetic Iron Oxide Particles After Intramyocardial Transplantation in Patients With Chronic Ischemic Heart Disease",
      "Acronym": "USPIO-MSC"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2013",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "August 23, 2018",
      "StudyFirstSubmitQCDate": "August 27, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 29, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "August 27, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 29, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Anders Bruun Mathiasen",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Rigshospitalet, Denmark"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Rigshospitalet, Denmark",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To evaluate the ability to trace iron oxide-labeled mesenchymal stromal cells with magnetic resonance imaging (MRI) after NOGA-guided injection therapy into the myocardium in patients with ischemic heart disease.",
      "DetailedDescription": "Aims:\n\nTo evaluate the ability to trace iron oxide-labeled mesenchymal stromal cells with magnetic resonance imaging (MRI) after NOGA-guided injection therapy into the myocardium.\n\nTo evaluate the safety and efficacy of treatment with iron oxide-labeled mesenchymal stromal cells to form new heart muscle cells and blood vessels in the myocardium submitted by NOGA-guided injection therapy in the myocardium in order to improve myocardial blood flow and reduce patients' symptoms.\n\nPatient Population:\n\nPatients with coronary artery disease not treatable with additional bypass surgery or percutaneous coronary intervention who have angina pectoris (Canadian Cardiovascular Society (CCS) class II-III) or angina equivalent shortness of breath (New York Heart Association (NYHA) class II -III).\n\nStudy Design A prospective, non-randomized, pilot study including 5-10 patients. Patients will by means of the percutaneous NOGA injection catheter system receive 12-15 intramyocardial injections. The number depending on the amount of cultured cells and distributed uniformly in the peripheral zone of a presumed ischemic area in the left ventricle demonstrated by angiography, magnetic resonance imaging and NOGA mapping."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Ischemic Heart Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "5",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "USPIO labeled MSC injection",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "USPIO labeled MSC injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Combination Product: USPIO labeled MSC injection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Combination Product",
            "InterventionName": "USPIO labeled MSC injection",
            "InterventionDescription": "USPIO labeled MSC injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "USPIO labeled MSC injection"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "MSC identification using MRI in-vivo on day 0",
            "PrimaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 0 after injection into the myocardium by MRI.",
            "PrimaryOutcomeTimeFrame": "24 hours"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo on day 1",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 1",
            "SecondaryOutcomeTimeFrame": "1 day"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo on day 7",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 7",
            "SecondaryOutcomeTimeFrame": "7 days"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo after 2 weeks",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 2 weeks",
            "SecondaryOutcomeTimeFrame": "2 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo after 4 weeks",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 4 weeks",
            "SecondaryOutcomeTimeFrame": "4 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo after 8 weeks",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 8 weeks",
            "SecondaryOutcomeTimeFrame": "8 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo after 12 weeks",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "MSC identification using MRI in-vivo after 26 weeks",
            "SecondaryOutcomeDescription": "Being able to identify the iron-oxide labeled mesenchymal stromal cells after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Cardiac pump function changes",
            "SecondaryOutcomeDescription": "Left ventricular ejection fraction, systolic and diastolic volumes after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Cardiac pump function changes",
            "SecondaryOutcomeDescription": "Left ventricular ejection fraction, systolic and diastolic volumes after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "CCS class",
            "SecondaryOutcomeDescription": "Canadian Cardiovascular Society (CCS) class after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "CCS class",
            "SecondaryOutcomeDescription": "Canadian Cardiovascular Society (CCS) class after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Seattle Angina Questionnaire",
            "SecondaryOutcomeDescription": "Seattle Angina Questionnaire after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Seattle Angina Questionnaire",
            "SecondaryOutcomeDescription": "Seattle Angina Questionnaire after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Weekly number of angina attacks",
            "SecondaryOutcomeDescription": "Weekly number of angina attacks after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Weekly number of angina attacks",
            "SecondaryOutcomeDescription": "Weekly number of angina attacks after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Weekly nitroglycerin consumption",
            "SecondaryOutcomeDescription": "Weekly nitroglycerin consumption after 12 weeks",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Weekly nitroglycerin consumption",
            "SecondaryOutcomeDescription": "Weekly nitroglycerin consumption after 26 weeks",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Adverse events",
            "SecondaryOutcomeDescription": "Adverse events registration",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge between 30 and 80 years.\nSigned informed consent.\nChronic stable ischemic heart disease\nNew York Heart Association (NYHA) class II-IV or Canadian Cardiovascular Society (CCS) class II-IV\nMaximal tolerable angina and/or heart failure medication.\nAngiography within 12 months of inclusion. Angiography must have at least one larger coronary vessel with a significant stenosis with no option for revascularization (Angiographies evaluated by an independent thoracic surgeon and an interventional cardiologist).\nPatients who have had revascularization done within 6 months of inclusion must have a new angiography at least 4 months after the intervention to rule out early restenosis.\n\nExclusion Criteria:\n\nPregnant or fertile women.\nClinical significant anemia, leukopenia, leukocytosis or thrombocythemia.\nDiminished functional capacity for other reasons such as: chronic obstructive pulmonary disease (COLD) with Forced Expiratory Volume in 1 second (FEV1)<1 L/min, moderate to severe claudication or morbid obesity.\nPatients with reduced immune response or treated with immunosuppressive medication.\nModerate to severe valvular disease or valvular disease with option for valvular surgery.\nAcute coronary syndrome with elevation of coronary markers, stroke or Transitory Cerebral Ischemia (TCI) within 6 weeks of inclusion.\nHistory with malignant disease within 5 years of inclusion or suspected malignity.\nOther experimental treatment within 4 weeks of baseline evaluation.\nOther revascularization treatment within 4 months of treatment.\nContraindications for Magnetic Resonance Imaging (MRI) such as: Claustrophobia, pacemaker, Implantable Cardioverter Defibrillator (ICD) unit, metal fragments or metal implants in the cranium",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jens Kastrup, MD DMSc",
            "OverallOfficialAffiliation": "The Heart Centre, Rigshospitalet, University of Copenhagen",
            "OverallOfficialRole": "Study Director"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23577035",
            "ReferenceType": "background",
            "ReferenceCitation": "Mathiasen AB, Hansen L, Friis T, Thomsen C, Bhakoo K, Kastrup J. Optimal labeling dose, labeling time, and magnetic resonance imaging detection limits of ultrasmall superparamagnetic iron-oxide nanoparticle labeled mesenchymal stromal cells. Stem Cells Int. 2013;2013:353105. doi: 10.1155/2013/353105. Epub 2013 Mar 19."
          },
          {
            "ReferencePMID": "24734781",
            "ReferenceType": "background",
            "ReferenceCitation": "Hansen L, Hansen AB, Mathiasen AB, Ng M, Bhakoo K, Ekblond A, Kastrup J, Friis T. Ultrastructural characterization of mesenchymal stromal cells labeled with ultrasmall superparamagnetic iron-oxide nanoparticles for clinical tracking studies. Scand J Clin Lab Invest. 2014 Aug;74(5):437-46. doi: 10.3109/00365513.2014.900698. Epub 2014 Apr 15."
          },
          {
            "ReferencePMID": "31814830",
            "ReferenceType": "derived",
            "ReferenceCitation": "Mathiasen AB, Qayyum AA, JÃ¸rgensen E, Helqvist S, Ekblond A, Ng M, Bhakoo K, Kastrup J. In Vivo MRI Tracking of Mesenchymal Stromal Cells Labeled with Ultrasmall Paramagnetic Iron Oxide Particles after Intramyocardial Transplantation in Patients with Chronic Ischemic Heart Disease. Stem Cells Int. 2019 Nov 14;2019:2754927. doi: 10.1155/2019/2754927. eCollection 2019."
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006331",
            "ConditionMeshTerm": "Heart Diseases"
          },
          {
            "ConditionMeshId": "D000017202",
            "ConditionMeshTerm": "Myocardial Ischemia"
          },
          {
            "ConditionMeshId": "D000003324",
            "ConditionMeshTerm": "Coronary Artery Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000003327",
            "ConditionAncestorTerm": "Coronary Disease"
          },
          {
            "ConditionAncestorId": "D000001161",
            "ConditionAncestorTerm": "Arteriosclerosis"
          },
          {
            "ConditionAncestorId": "D000001157",
            "ConditionAncestorTerm": "Arterial Occlusive Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafAsFound": "Heart Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafAsFound": "Ischemic Heart Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemic Heart Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5701",
            "ConditionBrowseLeafName": "Coronary Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3621",
            "ConditionBrowseLeafName": "Arteriosclerosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3617",
            "ConditionBrowseLeafName": "Arterial Occlusive Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M9685",
            "InterventionBrowseLeafName": "Iron",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Micro",
            "InterventionBrowseBranchName": "Micronutrients"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}